Prozkoumejte nejčtenější články a videa na Campus Sanofi
Hier vindt u interessante informatie en hulpmiddelen voor u en uw diabetespatiënten die ervoor kiezen om te vasten tijdens de Ramadan.
Explora la conexión entre intestino y cerebro, su impacto en la salud infantil y cómo mantener un equilibrio saludable.
The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
PRALUENT: a PCSK9i that ticks all the boxes1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
PRALUENT®: a PCSK9i that ticks all the boxes1–4
PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
Bricout H, Levant MC, Assi N, Crépey P, Descamps A, Mari K, Gaillat J, Gavazzi G, Grenier B, Launay O, Mosnier A, Raguideau F, Watier L, Harris RC, Chit A. Clin Microbiol Infect. August 2024.